Helicobacter pylori: Immunoproteomics related to different pathologies

Expert Review of Proteomics

Volumn 4, Issue 5, 2007, Pages 679-689

  Bernardini, Giulia ^a   Braconi, Daniela ^a   Lusini, Paola ^a   Santucci, Annalisa ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Antigen; Electrophoresis; Helicobacter pylori; Humoral response; Immunoblotting

Indexed keywords

AHPC PROTEIN; ANTIBIOTIC AGENT; ANTIGEN; BACTERIAL VACCINE; BIPA PROTEIN; GENE PRODUCT; KATA PROTEIN; PROTEIN DNAK; TYPA PROTEIN; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; ATROPHIC GASTRITIS; BACTERIAL INFECTION; DRUG SCREENING; GRAM NEGATIVE BACTERIUM; HELICOBACTER PYLORI; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOREACTIVITY; LYMPHOMA; MEDICAL INFORMATION; NONHUMAN; PROTEIN ANALYSIS; PROTEOMICS; REVIEW; SEROLOGY; STOMACH ULCER; VIRULENCE; WESTERN BLOTTING;

GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROTEOMICS; STOMACH; VIRULENCE FACTORS;

BACTERIA (MICROORGANISMS); HELICOBACTER PYLORI; NEGIBACTERIA;

EID: 35448987591     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.4.5.679     Document Type: Review

References (81)

1. Portal-Celhay C, Perez-Perez GI. Immune responses to Helicobacter pylori colonization: mechanisms and clinical outcomes. Clin. Sci. (Lond). 110(3), 305-314 (2006). •• Very good review on Helicobacter pylori epidemiology and pathogenesis.
2. IARC, in IARC Working Group on the evaluation of carcinogenic risk to humans. Lyon, France, 61, 1-261 (1994).
3. Hellstrom PM. This year's Nobel Prize to gastroenterology: Robin Warren and Barry Marshall awarded for their discovery of Helicobacter pylori as pathogen in the gastrointestinal tract. World J. Gastroenterol. 12(19), 3126-3127 (2006).
4. Prinz C, Hafsi N, Voland P. Helicobacter pylori virulence factors and the host immune response: implications for therapeutic vaccination. Trends Microbiol. 11(3), 134-138 (2003). • Excellent review on H. pylori virulence factor and host immune response, as well as their implications for therapeutic vaccination.
5. Kim YS, Kim JS, Jung HC et al. Regression of low-grade gastric mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: possible association with p16 hypermethylation. J. Gastroenterol. 37(1), 17-22 (2002).
6. Patel P, Mendall MA, Carrington D et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. Br. Med. J. 311(7007), 711-714 (1995).
7. Gasbarrini A, Serricchio M, Tondi P, Gasbarrini G, Pola P. Association of Helicobacter pylori infection with primary Raynaud phenomenon. Lancet 348(9032), 966-967 (1996). •• Describes the possible association of H. pylori and extradigestive diseases, particularly with primary Raynaud phenomenon.
8. Leontiadis GI, Sharma VK, Howden CW. Non-gastrointestinal tract associations of Helicobacter pylori infection. Arch. Intern. Med. 159(9), 925-940 (1999).
9. Reinauer S, Megahed M, Goerz G et al. Schonlein-Henoch purpura associated with gastric Helicobacter pylori infection. J. Am. Acad. Dermatol. 33(5 Pt 2), 876-879 (1995).
10. de Luis DA, Varela C, de La Calle H et al. Helicobacter pylori infection is markedly increased in patients with autoimmune atrophic thyroiditis. J. Clin. Gastroenterol. 26(4), 259-263 (1998).
11. Rebora A, Drago F, Picciotto A. Helicobacter pylori in patients with rosacea. Am. J. Gastroenterol. 89(9), 1603-1604 (1994).
12. Tebbe B, Geilen CC, Schulzke JD, Bojarski C, Radenhausen M, Orfanos CE. Helicobacter pylori infection and chronic urticaria. J. Am. Acad. Dermatol. 34(4), 685-686 (1996).
13. Nilsson HO, Pietroiusti A, Gabrielli M, Zocco MA, Gasbarrini G, Gasbarrini A. Helicobacter pylori and extragastric diseases - other Helicobacters. Helicobacter 10(Suppl. 1), 54-65 (2005). •• Describes the involvement of H. pylori in the pathogenesis of extragastric diseases. Although contradictory findings have been reported, the authors assume an important role of H. pylori in the development of cardiovascular and hematologic disorders.
14. Shang J, Pena AS. Multidisciplinary approach to understand the pathogenesis of gastric cancer. World J. Gastroenterol. 11(27), 4131-4139 (2005).
15. Janulaityte-Günther D, Kupcinskas L, Pavilonis A, Valuckas K, Wadström T, Andersen LP. Combined serum IgG response to Helicobacter pylori VacA and CagA predicts gastric cancer. FEMS Immunol. Med. Microbiol. 50(2), 220-225 (2007).
16. Lepper PM, Moricke A, Vogt K, Bode G, Trautmann M. Comparison of different criteria for interpretation of immunoglobulin G immunoblotting results for diagnosis of Helicobacter pylori infection. Clin. Diagn. Lab. Immunol. 11(3), 569-576 (2004).
17. Palestro G, Pellicano R, Fronda GR et al. Prevalence of Helicobacter pylori infection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest Italy. World J. Gastroenterol. 11(45), 7131-7135 (2005).
18. Held M, Engstrand L, Hansson LE, Bergstrom R, Wadstrom T, Nyren O. Is the association between Helicobacter pylori and gastric cancer confined to CagA-positive strains? Helicobacter 9(3), 271-277 (2004).
19. Sokic-Milutinovic A, Wex T, Todorovic V, Milosavljevic T, Malfertheiner P. Anti-CagA and anti-VacA antibodies in Helicobacter pylori-infected patients with and without peptic ulcer disease in Serbia and Montenegro. Scand. J. Gastroenterol. 39(3), 222-226 (2004).
20. Ables AZ, Simon I, Melton ER et al. Update on Helicobacter pylori treatment. Am. Fam. Physician 75(3), 351-358 (2007).
21. Krogfelt KA, Lehours P, Megraud F et al. Diagnosis of Helicobacter pylori infection. Helicobacter 10(Suppl 1), 5-13 (2005).
22. Linz B, Balloux F, Moodley Y et al. An African origin for the intimate association between humans and Helicobacter pylori. Nature 445(7130), 915-918 (2007). • Original publication about the use of sequences from a large data set of bacterial strains in order to demonstrate the intimate association between H. pylori and the anatomically modern humans before their migration from Africa.
23. Baldari CT, Lanzavecchia A, Telford JL et al. Immune subversion by Helicobacter pylori. Trends Immunol. 26(4), 199-207 (2005). • Demonstrates the mechanism and bacterial factors involved in immune subversion, thus opening the possibility of a better understanding of the pathogenicity of this microorganism.
24. Clyne M, Thomas J, Weaver L, Drumm B. In vitro evaluation of the role of antibodies against Helicobacter pylori in inhibiting adherence of the organism to gastric cells. Gut 40(6), 731-738 (1997). •• Describes the minimal inhibitory effect secretory IgA has on H. pylori adherence.
25. Chang CS, Chen LT, Yang JC, Lin JT, Chang KC, Wang JT. Isolation of a Helicobacter pylori protein, FldA, associated with mucosa-associated lymphoid tissue lymphoma of the stomach. Gastroenterology 117(1), 82-88 (1999).
26. Bumann D, Meyer TF, Jungblut PR et al. Proteome analysis of the common human pathogen Helicobacter pylori. Proteomics 1(4), 473-479 (2001). •• This review summarizes the information obtained for H. pylori proteins using a variety of proteomic techniques.
27. Klade CS. Proteomics approaches towards antigen discovery and vaccine development. Curr. Opin. Mol. Ther. 4(3), 216-223 (2002). • Describes the importance of classical proteomics and immunoproteomics approaches, such as serological proteome analysis (SERPA), in the discovery of novel vaccine candidates.
28. Sanchez-Campillo M, Bini L, Comanducci M et al. Identification of immunoreactive proteins of Chlamydia trachomatis by Western blot analysis of a two-dimensional electrophoresis map with patient sera. Electrophoresis 20(11), 2269-2279 (1999).
29. Nowalk AJ, Gilmore RD Jr, Carroll JA et al. Serologic proteome analysis of Borrelia burgdorferi membrane-associated proteins. Infect. Immun. 74(7), 3864-3873 (2006).
30. Vytvytska O, Nagy E, Blüggel M et al. Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis. Proteomics 2(5), 580-590 (2002).
31. Ariel N, Zvi A, Makarova KS et al. Genome-based bioinformatic selection of chromosomal Bacillus anthracis putative vaccine candidates coupled with proteomic identification of surface-associated antigens. Infect. Immun. 71(8), 4563-4579 (2003).
32. Jungblut PR. Proteome analysis of bacterial pathogens. Microbes. Infect. 3(10), 831-840 (2001). •• Basic fundamental paper regarding the proteomics of microbial pathogens.
33. Serruto D, Adu-Bobie J, Capecchi B, Rappuoli R, Pizza M, Masignani V. Biotechnology and vaccines: application of functional genomics to Neisseria meningitidis and other bacterial pathogens. J. Biotechnol. 113(1-3), 15-32 (2004).
34. Cash P. Proteomics in medical microbiology. Electrophoresis 21(6), 1187-1201 (2000). • Basic fundamental paper regarding the proteomics of microbial pathogens.
35. Shahjahan K. The current status of Helicobacter pylori vaccines: a review. Helicobacter 12, 89-102 (2007).
36. Tomb JF, White O, Kerlavage AR et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388(6642), 539-547 (1997).
37. Alm RA, Ling LS, Moir DT et al. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 397(6715), 176-180 (1999).
38. Oh JD, Kling-Backhed H, Giannakis M et al. The complete genome sequence of a chronic atrophic gastritis Helicobacter pylori strain: evolution during disease progression. Proc. Natl Acad. Sci. USA 103(26), 9999-10004 (2006).
39. Nilsson I, Utt M, Nilsson HO, Ljungh A, Wadstrom T. Two-dimensional electrophoretic and immunoblot analysis of cell surface proteins of spiral-shaped and coccoid forms of Helicobacter pylori. Electrophoresis 21(13), 2670-2677 (2000).
40. Utt M, Nilsson I, Ljungh A, Wadstrom T. Identification of novel immunogenic proteins of Helicobacter pylori by proteome technology. J. Immunol. Methods 259(1-2), 1-10 (2002). •• Application of immunoproteomics techniques to cell surface proteins of H. pylori.
41. Nilsson CL, Larsson T, Gustafsson E, Karlsson KA, Davidsson P. Identification of protein vaccine candidates from Helicobacter pylori using a preparative twodimensional electrophoretic procedure and mass spectrometry. Anal. Chem. 72(9), 2148-2153 (2000).
42. Jungblut PR, Bumann D, Haas G et al. Comparative proteome analysis of Helicobacter pylori. Mol. Microbiol. 36(3), 710-725 (2000). •• One among the very first papers on immunoproteomics of H. pylori introducing the Berlin 2D-abg database.
43. Haas G, Karaali G, Ebermayer K et al. Immunoproteomics of Helicobacter pylori infection and relation to gastric disease. Proteomics 2(3), 313-324 (2002).
44. Kimmel B, Bosserhoff A, Frank R, Gross R, Goebel W, Beier D. Identification of immunodominant antigens from Helicobacter pylori and evaluation of their reactivities with sera from patients with different gastroduodenal pathologies. Infect. Immun. 68(2), 915-920 (2000). •• First published study using sera from H. pylori-infected patients suffering from different gastroduodenal pathologies.
45. McAtee CP, Lim MY, Fung K et al. Identification of potential diagnostic and vaccine candidates of Helicobacter pylori by two-dimensional gel electrophoresis, sequence analysis, and serum profiling. Clin. Diagn. Lab. Immunol. 5(4), 537-542 (1998).
46. Krah A, Miehlke S, Pleissner KP et al. Identification of candidate antigens for serologic detection of Helicobacter pylori-infected patients with gastric carcinoma. Int. J. Cancer 108(3), 456-463 (2004). •• Immunoproteomics analysis of 60 sera from two clinically divergent conditions.
47. Mini R, Figura N, D'Ambrosio C et al. Helicobacter pylori immunoproteomes in case reports of rosacea and chronic urticaria. Proteomics 5(3), 777-787 (2005). •• First published study using an immunoproteomics approach to establish a correlation between H. pylori infection and skin disorders. IgA, IgG and IgE-medieted immune response were analyzed.
48. Bumann D, Jungblut PR, Meyer TF. Helicobacter pylori vaccine development based on combined subproteome analysis. Proteomics 4(10), 2843-2848 (2004). • Conventional and proteomics approaches of H. pylori antigen selection.
49. McAtee CP, Lim MY, Fung K et al. Characterization of a Helicobacter pylori vaccine candidate by proteome techniques. J. Chromatogr. B Biomed. Sci. Appl. 714(2), 325-333 (1998).
50. Everhart JE, Kruszon-Moran D, Perez-Perez G. Reliability of Helicobacter pylori and CagA serological assays. Clin. Diagn. Lab. Immunol. 9(2), 412-416 (2002).
51. + in a Mexican population. J. Gastroenterol. 39(12), 1138-1142 (2004).
52. Nomura AM, Lee J, Stemmermann GN, Nomura RY, Perez-Perez GI, Blaser MJ. Helicobacter pylori CagA seropositivity and gastric carcinoma risk in a Japanese American population. J. Infect. Dis. 186(8), 1138-1144 (2002).
53. Mini R, Bernardini G, Salzano AM et al. Comparative proteomics and immunoproteomics of Helicobacter pylori related to different gastric pathologies. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 833(1), 63-79 (2006). •• Introduces the importance of the strain that is used for immunoblotting, due to the different antigenic repertoires each strain possesses.
54. Mini R, Annibale B, Lahner E, Bernardini G, Figura N, Santucci A. Western blotting of total lysate of Helicobacter pylori in cases of atrophic body gastritis. Clin. Chem. 52(2), 220-226 (2006). •• Reinforces the hypothesis that the infection could have a specific role in atrophic body gastritis and proposes western blotting as a noninvasive serology test offering a realistic actual view of infection.
55. Lin YF, Wu MS, Chang CC et al. Comparative immunoproteomics of identification and characterization of virulence factors from Helicobacter pylori related to gastric cancer. Mol. Cell. Proteomics 5(8), 1484-1496 (2006). •• Identification and characterization of GroES as a predictive marker of gastric carcinoma.
56. Correa P. The gastric microenvironment determines Helicobacter pylori colonization. Am. J. Gastroenterol. 90(9), 1379-1381 (1995). • Many factors, including the genetic make-up of the host, diet and virulence factors of the bacteria, may explain the divergent pathways of H. pylori infection.
57. Prinz C, Schwendy S, Voland P. H. pylori and gastric cancer: shifting the global burden. World J. Gastroenterol. 12(34), 5458-5464 (2006).
58. Karnes WE Jr, Samloff IM, Siurala M et al. Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis. Gastroenterology 101(1), 167-174 (1991).
59. 13C-urea breath test, and serology. Scand. J. Gastroenterol. 35(2), 138-141 (2000).
60. Kokkola A, Rautelin H, Puolakkainen P et al. Positive result by serology indicates active Helicobacter pylori infection in patients with atrophic gastritis. J. Clin. Microbiol. 36(6), 1808-1810 (1998).
61. El-Omar EM, Oien K, El-Nujumi A et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 113(1), 15-24 (1997).
62. Annibale B, Aprile MR, D'ambra G, Caruana P, Bordi C, Delle Fave G. Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia. Aliment. Pharmacol. Ther. 14(5), 625-634 (2000). • This study confirms the body atrophy reduction and a clear-cut reduction in chronic inflammation after H. pylori eradication, but no effects were observed on atrophy or intestinal metaplasia.
63. Faisal MA, Russell RM, Samloff IM, Holt PR. Helicobacter pylori infection and atrophic gastritis in the elderly. Gastroenterology 99(5), 1543-1544 (1990).
64. Liston R, Pitt MA, Banerjee AK. IgG ELISA antibodies and detection of Helicobacter pylori in elderly patients. Lancet 347(8996), 269 (1996).
65. Kokkola A, Sipponen P, Rautelin H et al. The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia. Aliment. Pharmacol. Ther. 16(3), 515-520 (2002).
66. Lahner E, Bordi C, Di Giulio E et al. Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment. Aliment. Pharmacol. Ther. 16(3), 507-514 (2002).
67. Lahner E, Vaira D, Figura N et al. Role of noninvasive tests (C-urea breath test and stool antigen test) as additional tools in diagnosis of Helicobacter pylori infection in patients with atrophic body gastritis. Helicobacter 9, 436-442 (2004).
68. Annibale B, Di Giulio E, Caruana P et al. The long-term effects of cure of Helicobacter pylori infection on patients with atrophic body gastritis. Aliment. Pharmacol. Ther. 16(10), 1723-1731 (2002).
69. Uemura N, Mukai T, Okamoto S et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol. Biomarkers Prev. 6(8), 639-642 (1997).
70. Satoh K, Kimura K, Taniguchi Y et al. Biopsy sites suitable for the diagnosis of Helicobacter pylori infection and the assessment of the extent of atrophic gastritis. Am. J. Gastroenterol. 93(4), 569-573 (1998).
71. Annibale B, Lahner E, Santucci A et al. CagA and VacA are immunoblot markers of past Helicobacter pylori infection in atrophic body gastritis. Helicobacter 12(1), 23-30 (2007). •• Suggests a hidden role of H. pylori infection in gastric atrophy in all patients with atrophic body gastritis defined as H. pylori negative by conventional methods, because immunoblotting against H. pylori virulence factors is also able to prove a past exposure to infections in these patients.
72. Voland P, Weeks DL, Vaira D, Prinz C, Sachs G. Specific identification of three low molecular weight membrane-associated antigens of Helicobacter pylori. Aliment. Pharmacol. Ther. 16, 533-544 (2002).
73. Stoicov C, Saffari R, Cai X, Hasyagar C, Houghton J. Molecular biology of gastric cancer: helicobacter infection and gastric adenocarcinoma: bacterial and host factors responsible for altered growth signaling. Gene 341, 1-17 (2004).
74. Sorberg M, Engstrand L, Strom M, Jonsson KA, Jorbeck H, Granstrom M. The diagnostic value of enzyme immunoassay and immunoblot in monitoring eradication of Helicobacter pylori. Scand. J. Infect. Dis. 29, 147-151 (1997).
75. Tang N, Tornatore P, Weinberger SR. Current developments in SELDI affinity technology. Mass Spectrom. Rev. 23(1), 34-44 (2004). •• Detailed review of SELDI technology.
76. Wen Y, Marcus EA, Matrubutham U, Gleeson MA, Scott DR, Sachs G. Acid-adaptive genes of Helicobacter pylori. Infect. Immun. 71(10), 5921-5939 (2003).
77. Merrell DS, Thompson LJ, Kim CC et al. Growth phase-dependent response of Helicobacter pylori to iron starvation. Infect. Immun. 71(11), 6510-6525 (2003).
78. Kim N, Marcus EA, Wen Y et al. Genes of Helicobacter pylori regulated by attachment to AGS cells. Infect. Immun. 72(4), 2358-2368 (2004).
79. Hess JL, Blazer L, Romer T, Faber L, Buller RM, Boyle MD. Immunoproteomics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 815(1-2), 65-75 (2005). •• New frontiers of immunoproteomics: specificity of antibody capture and precision of mass spectral analysis.
80. Al Dahouk S, Nöckler K, Scholz HC, Tomaso H, Bogumil R, Neubauer H. Immunoproteomic characterization of Brucella abortus 1119-3 preparations used for the serodiagnosis of Brucella infections. J. Immunol. Methods 309(1-2), 34-47 (2006).
81. Das S, Sierra JC, Soman KV et al. Differential protein expression profiles of gastric epithelial cells following Helicobacter pylori infection using ProteinChips. J. Proteome Res. 4(3), 920-930 (2005).